Abdominal Aortic Aneurysm: The Complete Clinical Picture — Size, Risk, Surveillance, and Treatment

In short: An abdominal aortic aneurysm (AAA) is an abnormal widening of the main artery running through the abdomen, generally defined once it reaches 3.0 cm or more. Most are discovered incidentally — on a scan done for an unrelated reason — because they rarely cause symptoms until they rupture. The central clinical question isn't "do I have one," it's "how big is it, how fast is it growing, and when does watching stop being the right answer." Screening recommendations differ meaningfully by sex and smoking history. Treatment, when it's needed, involves a genuine trade-off between two approaches whose advantages shift depending on how far into the future you're looking.

What an Aneurysm Actually Is

A healthy abdominal aorta is normally around 2 cm wide. An aneurysm is a weakening and bulging of the vessel wall that allows it to widen abnormally — generally considered an aneurysm once it reaches 3.0 cm. Unlike a blockage, which restricts blood flow, an aneurysm is a structural problem: the wall itself is losing its ability to withstand the pressure of blood moving through it. Left alone, that weakening tends to progress gradually over time, and in a minority of cases, eventually reaches a point where the wall can no longer hold — a rupture.

This progression is usually silent. Most aneurysms cause no symptoms at all until rupture, which is part of why so many are found incidentally — during a scan ordered for back pain, kidney stones, or something else entirely unrelated.

Why Size (and Growth) Matter So Much

Diameter is the single most useful predictor available for estimating rupture risk, and the relationship isn't subtle. Annual rupture risk for a 4.0–4.9 cm aneurysm is estimated at roughly 0.5–5%; for a 5.0–5.9 cm aneurysm, that climbs to roughly 3–15%. Growth rate also tracks with size — aneurysms around 3 cm tend to grow about 1.3 mm per year on average, while those closer to 5 cm grow faster, around 3.6 mm per year. A growth rate of half a centimeter or more within a single year is itself considered a high-risk feature, independent of the absolute size.

Here's the number that puts this in perspective: rupture carries a mortality rate of roughly 50–80%. Elective, planned repair — done before rupture, on your own schedule — carries a mortality risk of only around 2–4%. That contrast is the entire reason surveillance and timed intervention exist as a strategy in the first place.

Who Gets Screened — and Why the Answer Differs by Sex

Screening recommendations aren't uniform, and the reasoning behind the differences is worth understanding rather than just memorizing. Major guidelines recommend one-time ultrasound screening for men aged 65–75 who have ever smoked — this group sees the clearest, most consistently demonstrated benefit. For men in that age range who've never smoked, screening is offered more selectively, based on individual conversation rather than a blanket recommendation.

For women, the picture is more complicated, and the reasoning matters. Women have a lower overall prevalence of AAA than men, and historically, screening trials haven't shown the same clear mortality benefit in women as in men — leading some major guidelines to recommend against routine screening in women with no smoking history or family history. But that's not the full picture: women with a genuine risk profile (smoking history, family history) have a prevalence approaching that of male smokers. The Society for Vascular Surgery takes a more inclusive approach than general preventive-medicine guidelines, recommending screening for both men and women aged 65–75 with a smoking or family history.

Here's a detail worth knowing specifically: a growing body of evidence shows women tend to rupture at smaller diameters than men — in some analyses, a quarter to a third of women with AAA ruptured below the standard 5.5 cm threshold long used for both sexes, a number largely established using male-dominated trial data. In response, both the Society for Vascular Surgery and the European Society for Vascular Surgery now formally recommend a sex-specific threshold for elective repair: 5.5 cm in men, 5.0 cm in women. It's worth knowing this is a weaker-strength recommendation than the male threshold — the supporting evidence is less robust, partly because historical trials underrepresented women — and the science here continues to evolve. Some researchers are now even questioning whether the long-standing male threshold itself should be higher, closer to 6.0 cm, as more data accumulates. This is a field being actively refined, not a fixed, settled number.

Other established risk factors beyond sex and smoking include older age, hypertension, a first-degree relative with AAA, and the presence of other atherosclerotic disease, such as peripheral artery disease.

When Does Watching Stop Being the Right Answer?

For small, asymptomatic aneurysms, surveillance — periodic imaging to track size and growth — is the standard approach, not immediate intervention. Current guidance generally converges on elective repair being considered at the sex-specific thresholds above, a saccular (irregularly shaped, rather than uniformly tube-shaped) aneurysm regardless of size, or significant growth over a short period — even in a smaller aneurysm. Below those thresholds, multiple randomized trials have found that early repair doesn't improve outcomes compared to continued surveillance; the risk of surgery itself outweighs the risk the small aneurysm currently poses.

Symptoms change the calculation entirely. New or worsening abdominal or back pain in someone with a known aneurysm is treated as a possible sign of impending rupture, regardless of size, and warrants urgent evaluation.

EVAR or Open Repair — Why the "Better" Option Depends on the Timeframe

When repair is indicated, there are two fundamentally different approaches. Open surgical repair involves direct access to the aorta and replacing the weakened section with a graft. Endovascular aneurysm repair (EVAR) is less invasive — a stent-graft is placed from inside the blood vessel, usually through the groin, without open abdominal surgery.

In the short term, the comparison favors EVAR clearly: lower 30-day mortality, fewer perioperative complications, shorter recovery. For years, this made EVAR the increasingly dominant choice, particularly for patients with higher surgical risk.

But the longer-term picture complicates that story. Multiple randomized trials with extended follow-up — some out to 15 years — have found that the early survival advantage of EVAR narrows and, in some analyses, reverses: aneurysm-related mortality becomes higher in the EVAR group after roughly 6–8 years, driven largely by a meaningfully higher rate of reintervention. Lifetime reintervention risk after EVAR has been estimated as high as 20–30%, often related to one of a few specific problems: the stent-graft shifting out of its original position (called migration), blood finding its way around or through the graft and continuing to pressurize the aneurysm sac from the inside — called an endoleak, essentially meaning the repair isn't fully sealing off the weakened area the way it's supposed to — or the aneurysm continuing to grow around the device despite it being in place. Open repair, by contrast, has higher upfront risk but tends to be a more definitive, one-time solution once recovery is complete.

This is exactly why the choice isn't automatic — it depends on a genuine weighing of a patient's overall health, surgical risk, anatomy, and how much weight to place on short-term versus long-term outcomes, ideally made with a specialist who can walk through the specific trade-offs for that individual's case.

What Follow-Up Actually Looks Like

Treatment isn't the end of monitoring. Patients who've had EVAR specifically require ongoing periodic imaging — precisely because problems like a stent-graft shifting position or blood still reaching the aneurysm sac around the graft often cause no symptoms on their own, even though they can mean the repair isn't holding as expected. Open repair generally requires less intensive long-term imaging surveillance once initial recovery is confirmed, which is itself one of the practical trade-offs patients weigh alongside the upfront surgical risk.

Vascular Surgeon's Take

The conversation I have most often with patients isn't really about whether to treat — it's about helping someone understand that "5.5 cm" isn't a magic number that applies identically to everyone in the room. A woman's risk at a given size genuinely isn't the same as a man's, and a slowly stable 4.8 cm aneurysm is a fundamentally different situation from the same measurement with rapid recent growth. The size starts the conversation. It doesn't finish it.

The Bottom Line

An AAA is a structural weakening of the aorta, most often found without any symptoms, where the central question is size, growth rate, and — critically — individual risk factors including sex. Screening guidance varies meaningfully based on smoking history and sex, and both major vascular societies now formally recognize a lower repair threshold in women, reflecting real differences in rupture risk at a given size. When repair becomes appropriate, the choice between EVAR and open surgery is a genuine trade-off between early safety and long-term durability, not a simple "newer is better" decision — and ongoing surveillance remains part of the picture regardless of which approach is chosen.

References
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation, American Heart Association/American College of Cardiology.
Repair of Abdominal Aortic Aneurysms: JACC Focus Seminar, Part 1. Journal of the American College of Cardiology, 2022.
US Preventive Services Task Force. Screening for Abdominal Aortic Aneurysm: Recommendation Statement, 2019.
Sex-specific aortic diameter thresholds for AAA repair. Journal of Vascular Surgery (PMC8963251).
Endovascular versus open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK EVAR trial 1. The Lancet, 2016.
Long-term Outcomes Associated With Open vs Endovascular Abdominal Aortic Aneurysm Repair in a Medicare-Matched Database. JAMA Network Open.

Recommended Reading
How PAD Is Diagnosed and Treated (Clinical Deep Dive)